Compare Heron Therapeutics Inc (HRTX) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Vanguard Total Stock Market Index Fund ETF trades at $380.73 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 33818.6× Heron Therapeutics Inc's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| HRTX | VTI | |
|---|---|---|
Market Cap | $68.01M | $2.30T |
Volume | 1,891,941 | 2,982,924 |
Sector | Health | — |
52-Week High | $1.49 | $384.30 |
52-Week Low | $0.27 | $311.68 |
Typical Hold Time | 35 Days | 131 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
VTI trades at $381.03, down 0.39% on the day, with bullish technical signals from moving averages. The ETF maintains broad exposure to the entire U.S. equity market with over 3,500 holdings. Recent news highlights strong long-term performance potential, with $500 monthly investments since 2001 growing to approximately $876,000 according to The Motley Fool (2026-10-01).
VTI offers diversified U.S. stock market exposure with low expense ratios, making it suitable for long-term investors. Key risks include concentration in top holdings and market volatility. Analyst sentiment remains positive for buy-and-hold strategies, though current RSI levels suggest potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
